{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"NCT05983432","nct_id":"NCT05983432","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05983432. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks","label":"BL-B01D1 administered Day 1 and Day 8 per cycle","type":"EXPERIMENTAL"},{"description":"BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks","label":"BL-B01D1 administered Day 1 per cycle","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-07-22","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","Esophageal Cancer","Small Cell Lung Cancer","Nasopharyngeal Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Adenocarcinoma","Ovarian Cancer","Endometrial Cancer","Cervical Cancer","Triple Negative Breast Cancer"],"enrollment":{"count":540,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BL-B01D1","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-21","lead_sponsor":"SystImmune Inc.","official_title":"A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2030-04-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Participants with Dose-limiting toxicities","timeFrame":"One year"},{"measure":"Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs),","timeFrame":"One year"},{"measure":"Participants with abnormal physical examination findings","timeFrame":"One year"},{"measure":"Participants with ability to care for themselves, daily activity, and physical activity","timeFrame":"One year"},{"measure":"Participants with abnormal ECG reading","timeFrame":"One year"},{"measure":"Participants with abnormal lab results","timeFrame":"One year"},{"measure":"To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC","timeFrame":"One year"}],"references":[],"start_date":{"date":"2023-08-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05983432"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05983432"}